This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

The Irish Tax Man Strikes Again

NEW YORK (TheStreet) -- News that Actavis (ACT) has agreed to buy Forest Laboratories (FRX) for $25 billion puts a spotlight on Irish tax law.

Just last week, when I wrote about Mallinckrodt (MCK) buying Cadence (CAD), I noted in passing that while the Mallinckrodt name is German and the company's heritage is American, Mallinckrodt is technically based in Dublin.

What's going on here?

What's going on is that big companies are taking advantage of Ireland's low 12.5% corporate tax rate. Even that rate understates the country's tax advantage.

By using territorial taxation, which doesn't tax profits made outside the country at all, Ireland also gets around U.S. transfer pricing rules.

It's not just the tax rate that makes Ireland an attractive place to book profits, but what it actually calls subject to tax, the tax base. Ireland's is very low, making it very attractive to any company which, like a drug company, is based in intellectual property.

By placing intellectual property in an outright tax haven, such as Bermuda, and putting that under an Irish subsidiary, tech companies have avoided billions of dollars in U.S. tax over the years. By having two Irish units move costs from high-tax to low-tax countries, a strategy called the Double Irish, tax bills are reduced further.

Irish officials insist their country is not a tax haven, and some commentators here blame U.S. law rather than Irish law for all this, but the fact remains that Ireland is a great place to pretend to do business, even if the economy there is still recovering from the Great Recession. 

While Actavis keeps its administrative offices in New Jersey and does its distribution from Florida, its official headquarters is at 1 Grand Canal Square, in a warren of new construction near the Dublin docks, a space not much bigger than a Grand Cayman postal box. 

Forest posted about $157 million in net income for calender 2013 (its fiscal year ends in March), and its income before tax was $183 million. That barely scratches the surface of what accountants can do with Forest's numbers, using Irish tax law.

They must think they can do a lot. At $25 billion, Actavis is valuing Forest at about 7.3 times its current annual revenue. The deal comes less than a month after Forest announced it would buy Aptalis, best known for drugs to treat digestion problems for $2.9 billion. At the time of the acquisition, we reported Aptalis was expecting $700 million in revenue for fiscal 2015.

Forest has also begun a program aimed at cutting $500 million in expenses by 2016.

The Irish Development Authority is proud to note that nine of the top 10 largest drug companies are located in Ireland, with seven of the 10 largest drugs being produced there. But it's not because Irish scientists are the world's best. It's because Irish tax laws are the best in Europe, and some of the best anywhere.

All of which means that public companies technically based in Ireland have a big advantage in shopping for other companies, as Forest, Actavis and Mallinckrodt have just proven. Investors should expect others to follow their lead.

At the time of publication, the author owned no shares in companies mentioned here.

This article represents the opinion of a contributor and not necessarily that of TheStreet or its editorial staff.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,071.22 -41.93 -0.24%
S&P 500 1,977.80 -5.05 -0.25%
NASDAQ 4,505.8520 -6.3420 -0.14%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs